Providers

Risk-bearing provider organizations rely on physicians to achieve cost savings. The literature on physician-mediated interventions to reduce costs is scant and provides little guidance on effective strategies.

This study of 26,805 cardiologists shows that industry payments (averaging $3958) are linked to increased Medicare costs, with each $10,000 in payment associated with $14.1 higher beneficiary spending.

While clinicians prioritize rapid regrowth, patients with alopecia areata prioritize safety and shared decision-making.

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.

Genmab’s epcoritamab (Epkinly) streamlines bispecific antibody workflows for DLBCL and follicular lymphoma, cutting chair time, waste, and costs.

Artificial intelligence is emerging as a powerful tool for improving the diagnosis, phenotyping, and treatment of inflammatory skin diseases such as alopecia.

Machine learning–based risk prediction models, particularly gradient boosting, can accurately identify early clinical indicators of CKD.

Elevance Health's Shane Hochradel explains how the company tracks provider satisfaction and uses AI to cut administrative burden.

MASLD and type 2 diabetes are closely interconnected conditions driven by shared metabolic dysfunction that together increase the risk of liver disease progression, cardiovascular complications, and mortality.

Study links moderate to severe alopecia areata to higher atopic dermatitis risk, urging routine screening and smarter treatment choices.

Two analyses revealed significant delays and systemic barriers in the MS diagnostic journey alongside substantial clinical and economic burden in primary progressive MS.

Kavita Nair, PhD, discusses how clinicians select MS therapies, the role of cost and access, and why policy changes could threaten patient outcomes.

A global analysis found that although alopecia areata rates in young adults have modestly declined since 1990, the disease continues to disproportionately affect women and people in their early 30s.

Higher baseline monocyte counts, along with preserved basophils and low C-reactive protein, independently predict complete remission on anti-IgE therapy for CSU.

Many physicians are reluctant to test for Lp(a), in part because they are unclear how to manage patients with elevated levels.

Data suggest the benefits of zanubrutinib versus acalabrutinib in R/R chronic lymphocytic leukemia were even more pronounced in high-risk cases.

Patients with heart failure tended to have lower treatment intensity at hospital admission, but their cardiac load improved as blood pressure treatment intensified.

Experts at a roundtable in Boston, Massachusetts, on November 19, 2025, discussed multidisciplinary strategies for obesity care, including systemic and operational barriers and scalable solutions to promote patient ownership.

A new patient decision aid uses a staged approach to help adults with moderate to severe atopic dermatitis choose systemic treatments effectively.

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase.

Major and minor risk factors, including early eczema and delayed food introduction, shape childhood food allergy risk, a review found.

A new psoriasis severity tool called G2-PASE showed a strong correlation with PASI, potentially offering a simpler assessment for clinical practice.

Kavita Nair, PhD, discusses integrating neurology and pharmacy services to improve MS care coordination and reduce treatment delays.

Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.